
The Agentic Patient 2: One Tool, One Job - Cancer management AI toolset
Apr 30, 2026 - 43:26
Radio and PodcastLive Radio & Podcasts
1 view Mar 19, 2026 In-person video interviewsThe European Health Data Space (EHDS) isn't just a new regulation—it’s a "Magna Carta" for healthcare innovation. In this interview from the Smart Bridges Event, we sit down...
EHDS and Pharma: Impact on R&D and Unresolved Challenges is an episode from Faces of Digital Health by Tjasa Zajc. 1 view Mar 19, 2026 In-person video interviewsThe European Health Data Space (EHDS) isn't just a new regulation—it’s a "Magna...
This episode belongs to Faces of Digital Health.
Use the player on this page to stream the episode online.
Published Mar 19, 2026, 17:45 long, audio available.
1 view Mar 19, 2026 In-person video interviewsThe European Health Data Space (EHDS) isn't just a new regulation—it’s a "Magna Carta" for healthcare innovation. In this interview from the Smart Bridges Event, we sit down with industry expert Dennis Geisthardt, Head of digital.lab, to break down the implementation timeline (2025–2031) and what it means for the pharmaceutical industry, medtech, and patients across Europe. We dive into the "Countdown to 2027," the challenges of intellectual property vs. data sharing, and how opening up access to clinical data could finally unlock breakthroughs for rare diseases and personalized medicine. In this video, you’ll learn: The 3 major milestones of EHDS implementation (2027, 2029, 2031). Why "Primary Use" vs. "Secondary Use" of data matters for your healthcare. The risks and rewards for the private sector and Big Pharma. How EHDS could revolutionize market access (AMNOG) and AI-driven drug discovery. 00:30 – Introduction: The Smart Bridges Event 03:45 – Why EHDS is a 100-year milestone for healthcare 04:30 – The role of the private sector in co-creating the framework 04:10 – What is EHDS? Primary vs. Secondary data use explained 05:00 – The Timeline: The "Countdown" to 2027, 2029, and 2031 06:30 – Who is a "Data Holder"? (Hospitals, Pharma, & MedTech) 07:45 – Industry Challenges: IP Rights, Trade Secrets, and Competition 08:50 – Revolutionizing Market Access (AMNOG) through data 09:40 – A "Magna Carta" for Rare Diseases and AI Research 10:30 – Identifying why therapies work (or fail) using broader datasets 11:20 – Closing: Why EHDS requires a "European Village" to succeed
You can listen to EHDS and Pharma: Impact on R&D and Unresolved Challenges online on Radio and Podcast. Open the player on this page to stream the available audio.
EHDS and Pharma: Impact on R&D and Unresolved Challenges is an episode from Faces of Digital Health by Tjasa Zajc.
This episode is 17:45 long.
This episode was published on Mar 19, 2026.
Yes. Use the heart button on the episode page to add it to your favorite episodes list.
Yes. This page shows related episodes from Faces of Digital Health when more episodes are available from the podcast feed.
You can listen to EHDS and Pharma: Impact on R&D and Unresolved Challenges on this page when the episode audio is available from the podcast feed.
EHDS and Pharma: Impact on R&D and Unresolved Challenges is from Faces of Digital Health by Tjasa Zajc.
Published Mar 19, 2026 and 17:45 long